Navigation Links
Onyx Pharmaceuticals to Present at the Deutsche Bank 34th Annual Health Care Conference
Date:5/12/2009

EMERYVILLE, Calif., May 12 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at the Deutsche Bank 34th Annual Health Care Conference on Tuesday, May 19, at 2:35 p.m. Eastern Time. Interested parties may access a live webcast of the presentation on our website at:

http://www.onyx-pharm.com/wt/page/event_calendar

It is recommended that listeners log on 15 minutes early in order to register and download any necessary software. For those unable to participate during the live webcast, a recorded replay of the presentation will be available one hour following the conclusion of the presentation through June 19, 2009.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar(R), a small molecule drug. Nexavar is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. For more information about Onyx, visit the company's website at www.onyx-pharm.com.

Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer Pharmaceuticals Corporation.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Jiangbo Pharmaceuticals, Inc. to Present at CCG IRs China Rising Conference in New York
2. Vion Pharmaceuticals Reports 2009 First Quarter Results
3. Jiangbo Pharmaceuticals Announces New Ticker (JGBO) and CUSIP
4. Vanda Pharmaceuticals Announces Withdrawal of Director Nominees and Proposal to Liquidate Submitted by Tang Capital
5. Jazz Pharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
6. Photos: Generic Pharmaceuticals Saved $734 Billion over Last Decade
7. VIA Pharmaceuticals Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients Using Serial MDCT Imaging of Coronary Plaque
8. Valeant Pharmaceuticals to Present at Bank of America and Merrill Lynch 2009 Health Care Conference
9. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2009 Financial Results on May 7, 2009
10. Watson Pharmaceuticals Reports First Quarter 2009 Results; Raises 2009 Outlook
11. Conference Call Advisory - NUCRYST Pharmaceuticals Corp. Conference Call to Discuss 2009 First Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Raleigh, NC (PRWEB) , ... December 02, 2016 , ... ... the Open Enrollment Period (or Annual Election Period), is ending December 7th. Currently-enrolled Medicare ... plan (Part C) or prescription drug plan (Part D) need to make changes during ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... inspirational interview of two ostomy patients, standing as living proof that attitude and ... from digestive diseases and issues that spike around the holidays. This campaign will ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... of "Cardiovascular Health" in USA Today, which covers the innovative treatments, therapeutic technologies, ... while maintaining fulfilling lives. “We are prolonging life 6 years in the last ...
(Date:12/2/2016)... OH (PRWEB) , ... December 02, 2016 , ... ... of veterinarian diagnostic imaging systems and the first company to offer ... With a Heart at their tradeshow booth # 941 for the American Association ...
(Date:12/2/2016)... ... 02, 2016 , ... Yisrayl Hawkins, at The House of Yahweh in Abilene, ... into Bible Prophecy. Yisrayl says this generation, known as the Last Generation, started in ... the details line up exactly with Bible Prophecy – a protected way for those ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , Dec. 1, 2016  Today, Simpson Healthcare Executives, ... honor of being selected as winners of multiple awards ... Executives Website at the PLATINUM level, Blue Zones Menu ... at the GOLD Level, and our proprietary 3ConneX Platform ... Simpson Healthcare Executives, we are excited to showcase our ...
(Date:12/2/2016)... BRUSSELS , Dec. 2, 2016  UCB is pleased to ... presentation at the upcoming 70 th American Epilepsy Society ... Houston, TX , USA. 1-12 ... safety and efficacy profile of VIMPAT ® (lacosamide) CV ... also share findings on the current state of the union ...
(Date:12/2/2016)... Dec. 2, 2016 Allergan plc (NYSE: ... information on its previously announced Accelerated Share Repurchase (ASR) Program. ... ... As previously announced, the Company entered into a ... the Company will repurchase $10 billion of its ordinary shares. ...
Breaking Medicine Technology: